Annotation

The article discusses the legal problems that arise when importing medicines and medical devices into the Russian Federation by parallel import. The article analyzes changes in legislation on parallel imports after 2022, and examines judicial practice in disputes related to the turnover of medical products imported without the consent of the copyright holder. Special attention is paid to the analysis of the Roche Diagnostics Rus case, which revealed a conflict between the interests of intellectual property protection and the need to ensure the availability of medicines. Based on the conducted research, conclusions are drawn about the legal risks of participants in the turnover and directions for improving legislation are proposed. In preparing the article, both theoretical and empirical methods were used, which allowed for a comprehensive analysis of the legal regulation of parallel import of medicines in the Russian Federation.